Seth Berkley

I mean, 20% of the milk at one point was infected with virus.

Yes, but this is the point.

So we're not investing in these.

And the environment, the problem is, is that when the government – and you have to understand from an investor point of view, people are saying, okay, well, I don't know what the return is going to be because people don't care about this.

But the other side of it is –

you got to get these things through regulatory agencies.

And if the regulatory agencies are hostile to, you know, technologies like mRNA, et cetera, then you may have delays, which in, you know, delays in biotech is money.

So you've got academic investigators really doing exciting work.

Those need to be converted into, you know, trying to turn it into real products.

And there's not a lot of appetite right now for that.

And

So, I mean, in the area of AI crossover, there is some interest because, of course, there's a lot of funding available for AI, and you can do really amazing things, AI for good, by using it for these types of technologies.

But even then, you still have to turn them into vaccine products.

And mucosal vaccines, the same thing.

I mean, the barrier is potentially high on the regulatory side, but we need to work through that.

And

And today with AI, you can begin to do much better predictions of what's happening.

You can understand toxicities in silico.

You can begin to drive towards having, you know, really understanding exactly what you're doing.

And let's just remind people that the reason we had COVID vaccines in 327 days was because